A Study to Evaluate the Effect of Letrozole and Tamoxifen on Bone and Lipids in Postmenopausal Women With Breast Cancer
Status:
Completed
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
Estrogen is known to be a regulator of bone and lipid metabolism. Letrozole is a potent
inhibitor of estrogen synthesis.
This study evaluated the effects of letrozole and tamoxifen on bone and lipid metabolism in
postmenopausal women with resected, receptor positive early breast cancer.
Phase:
Phase 3
Details
Lead Sponsor:
Novartis Pharmaceuticals
Collaborators:
Danish Breast Cancer Cooperative Group University of Sheffield